Summary of the International Conference on Onco-Nephrology: an emerging field in medicine
Anna Capasso(Livestrong Foundation), Ferdinando De Vita(University of Campania "Luigi Vanvitelli"), Maurizio Gallieni(University of Milan), Davide Viggiano(Biogem), Franco Citterio, Giovambattista Capasso(Canon (Japan)), Lucia Altucci(Biogem), Farhad R. Danesh(The University of Texas MD Anderson Cancer Center), Mark A. Perazella(Yale University), Giovanni Gambaro(University of Verona), Hatem Amer(Mayo Clinic), Luigi Biancone(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Calvin J. Kuo(Stratford University), Ariga Akitaka, Bruno Daniele(Azienda Ospedaliera G.Rummo), Laura Cosmai(Associazione Italiana Di Oncologia Medica), Michele Caraglia(University of Campania "Luigi Vanvitelli"), Jolanta Małyszko, Antonietta D’Errico, Geppino Falco(Biogem), Joseph V. Bonventre(Brigham and Women's Hospital), Ariela Benigni(Mario Negri Institute for Pharmacological Research), Andrés Cervantes(INCLIVA Health Research Institute), Amit Alahoti, Francesco Trepiccione(Biogem), Giuseppe Grandaliano(University of Foggia), Todd Alexander, Antonio Ereditato, Giovanni Camussi(University of Turin), Loreto Gesualdo(Horta (Italy)), Vincenzo Barone(Istituto di Chimica Biomolecolare), Ariella Benigni(Mario Negri Institute for Pharmacological Research), Carmine Zoccali(Biogem), Giacomo Cartenì, Mitchell H. Rosner(University of Virginia Health System), Qi Qian(University of California, Los Angeles), Umberto Capitanio(IRCCS Ospedale San Raffaele), Edgar A. Jaimes(Memorial Sloan Kettering Cancer Center), Pierre Ronco(Inserm), Renato Franco, Denis Fouque(Université Claude Bernard Lyon 1), Vincenzo Di Marzo(Istituto di Chimica Biomolecolare)
Cited by 56
Related Papers
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
|Cell Death and Differentiation|2018|6.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients
|Journal of the American Society of Nephrology|2005|3.4k